GLP Watchdog

Foundayo vs Rybelsus (Being Discontinued in the US): Two Oral GLP-1s

Foundayo (orforglipron, Eli Lilly) vs Rybelsus (semaglutide (oral), Novo Nordisk)

Last verified November 2026

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The verdict

Both are pills; the similarity ends there. Rybelsus is a peptide that relies on an absorption enhancer, so it needs the fasting window; Foundayo is a non-peptide small molecule that survives stomach acid on its own. The efficacy gap is wide: ATTAIN-1 reported −11.1% at 72 weeks on the top dose, against −3.7 kg at 26 weeks on Rybelsus 14 mg in PIONEER 1, though those are different trials, populations and endpoints. Foundayo costs $149–$349 a month through LillyDirect, depending on dose. Rybelsus is being discontinued in the US, and its replacement, Ozempic tablets, costs $149–$299 a month self-pay.

Side-by-side comparison

Foundayo vs Rybelsus, side by side
FieldFoundayoRybelsus
MechanismNon-peptide small-molecule GLP-1 receptor agonistPeptide GLP-1 agonist (semaglutide + SNAC absorption enhancer)
Approved doses0.8 → 2.5 → 5.5 → 9 → 14.5 → 17.2 mg once daily3 mg → 7 mg → 14 mg once daily
Weight loss (max dose, obesity)−11.1% at 72 wk (ATTAIN-1, 17.2 mg; Foundayo label)−3.7 kg (about −4%) at 26 wk (PIONEER 1, 14 mg)
A1C reduction (T2D)About −1.5 points / 40 wk at the top dose (ACHIEVE-1; −1.24 to −1.48 across doses)−0.9% to −1.4% / 26 wk (PIONEER 1, 14 mg)
FDA-approved indicationChronic weight management in adults (April 2026)Type 2 diabetes (2019), including lowering heart risk; not weight
Once-daily food restrictionNone — take with or without food, any time of dayEmpty stomach + max 4 oz plain water + 30-min fast after
The complaint people report mostNausea, 26% to 35% and rising with dose (Foundayo label)Nausea, 20% at the 14 mg dose in the label's placebo-controlled trials
What it costs if you pay cash$149 to $349/mo through LillyDirect, by dose$149–$299/mo self-pay as Ozempic tablets, its US replacement

What each one costs in the compounded market

Standing monthly cash prices from the 734 sellers on this register. These are compounded preparations, not the approved products compared above.

Foundayo — orforglipron

from $269 /mo

1 sellers publish a standing price. This is the lowest of all 1; the median is $269 a month.

Where to get orforglipron — a selection of sellers, not a price ranking

Rybelsus — semaglutide (oral)

from $47 /mo

463 sellers publish a standing price. This is the lowest of all 463; the median is $174 a month.

Where to get semaglutide — a selection of sellers, not a price ranking

⚠ A compounded preparation is not the approved product. No agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed when the shortages closed. The price gap is real, and so is the difference in oversight. Every seller, with its price record.

Frequently asked questions

Which works better for weight loss, Foundayo or Rybelsus?

Foundayo recorded −11.1% at 72 wk (ATTAIN-1, 17.2 mg; Foundayo label); Rybelsus recorded −3.7 kg (about −4%) at 26 wk (PIONEER 1, 14 mg). These come from separate trials with different protocols and populations, so the gap between two numbers from two studies is weaker evidence than it looks. No head-to-head trial of this pair is on record here.

Are Foundayo and Rybelsus the same drug?

No. Foundayo is orforglipron and Rybelsus is semaglutide (oral) — different molecules, and they work differently: Non-peptide small-molecule GLP-1 receptor agonist against Peptide GLP-1 agonist (semaglutide + SNAC absorption enhancer). Results with one do not predict results with the other.

Is Foundayo or Rybelsus cheaper?

On the manufacturers' own cash pricing: Foundayo at $149 to $349/mo through LillyDirect, by dose, Rybelsus at $149–$299/mo self-pay as Ozempic tablets, its US replacement. That is the list-price comparison, and it is not what most people pay. What you actually pay depends on whether your plan covers it, which formulary tier it sits in, and whether you have met your deductible — and for many people the honest comparison is between an insured copay and a cash-pay compounded alternative rather than between these two figures.

What does a compounded version of each actually cost?

Across the 734 sellers in this register, the cheapest standing monthly cash prices we hold are orforglipron from $269 a month and semaglutide (oral) from $47 a month. A compounded preparation is not the approved product: no agency has reviewed that specific preparation for safety, effectiveness or manufacturing quality, and the legal ground under compounding these molecules narrowed once the shortages closed. The price gap is real and so is the difference in oversight.

Can I switch from Foundayo to Rybelsus?

Yes, with a prescriber. Expect to re-titrate from the bottom of the new drug's ladder rather than starting where you left off: these are different molecules and tolerance to one does not transfer to the other. Both the old drug's washout and the new drug's schedule apply.

Which one should I ask for?

That is a prescriber's call, and anyone answering it from a table is guessing. What a page like this can do is tell you what the trials measured, what the manufacturers charge, and where the evidence is still missing, so the conversation starts from the record rather than from an advertisement.

References

  1. 1.Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med. 2025. PMID: 40960239.
  2. 2.Rosenstock J, Hsia S, Nevarez Ruiz L, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes (ACHIEVE-1). N Engl J Med. 2025. PMID: 40544435.
  3. 3.Wharton S, Blevins T, Connery L, et al. Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (Phase 2). N Engl J Med. 2023. PMID: 37351564.
  4. 4.Ma X, Liu R, Pratt EJ, et al. Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist. Diabetes Ther. 2024. PMID: 38402332.
  5. 5.Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes. Diabetes Care. 2019. PMID: 31186300.
  6. 6.Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet. 2019. PMID: 31186120.
  7. 7.Novo Nordisk. RYBELSUS and OZEMPIC (semaglutide) tablets — Prescribing Information (revised January 2026). DailyMed (NIH/NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=27f15fac-7d98-4114-a2ec-92494a91da98
  8. 8.Novo Nordisk. Ozempic (semaglutide) pill available in the US starting May 4 (press release, May 1, 2026). Novo Nordisk US newsroom. 2026. https://www.novonordisk-us.com/media/news-archive/news-details.html?id=916540
  9. 9.Eli Lilly and Company Foundayo (orforglipron) tablets, prescribing information DailyMed (NLM). 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8ac446c5-feba-474f-a103-23facb9b5c62

Related comparisons

See the full drug-vs-drug verdict index or provider rankings.